Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026, in Orlando, Florida, highlighting the appointment of two new directors, Alessandro Puddu and Viorica Carlig, and outlining key progress in the development of AVERSA(TM) FENTANYL. During 2025, the company strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent protection including new U.S. and Macao patents, engaged with the U.S. Food and Drug Administration through a Type C meeting, and advanced branding initiatives for AVERSA(TM) FENTANYL. Looking ahead to 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug application, and initiating a Human Abuse Liability clinical study.

To view the full press release, visit https://ibn.fm/cp5lC

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Friday's trading session at $4.79, up 5.9735%, on 13,664 volume. The average volume for the last 3 months is 54,145 and the stock's 52-week low/high is $4.17/$11.6779.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting
• InvestorNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Sells 90% Stake in Pocono Pharmaceutical for $5 Million
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Strawberry Fields REIT Inc. (NYSE American: STRW)

The QualityStocks Daily Newsletter would like to spotlight Strawberry Fields REIT Inc. (NYSE American: STRW).

Strawberry Fields REIT (NYSE AMERICAN: STRW) announced that it will report its year-end 2025 financial results after market close on Feb. 19, 2026. The company will host a conference call and webcast on Feb. 20, 2026, at 11:00 a.m. Eastern time, during which management will discuss the results and provide an update for current and prospective investors.

To view the full press release, visit https://ibn.fm/80MrU

Strawberry Fields REIT Inc. (NYSE American: STRW) is a self-administered real estate investment trust engaged in the ownership, acquisition, development, and leasing of skilled nursing and other healthcare-related properties. Initially spun out in 2015 with a 33-property portfolio in Indiana and Illinois, the company has steadily expanded its footprint and now owns and leases across 10 states. Its facilities are leased to experienced third-party operators, primarily under long-term triple-net agreements.

The company’s disciplined strategy emphasizes working with regional operators and experienced consultants, focusing on markets where demographic tailwinds and regulatory barriers support long-term demand. From 2020 through projected 2025, the company achieved compound annual growth rates of 13.6% in Adjusted Funds From Operations (AFFO) and 13.5% in Adjusted EBITDA (AEBITDA).

In August 2025, the board of directors approved a 14.3% increase in the company’s quarterly dividend to $0.16 per share. Chairman and CEO Moishe Gubin stated that the dividend increase reflects the company’s strong performance and sustainable outlook, while still keeping the payout ratio below 50%.

Strawberry Fields REIT is headquartered in South Bend, Indiana.

Portfolio

As of September 2025, Strawberry Fields REIT owns and holds long-term leasehold interests in 142 healthcare facilities totaling more than 15,500 licensed beds. The portfolio includes 130 skilled nursing facilities (SNFs), 10 assisted living facilities (ALFs), and two long-term acute care hospitals (LTACHs), with properties located in Arkansas, Illinois, Indiana, Kansas, Kentucky, Missouri, Ohio, Oklahoma, Tennessee, and Texas.

In recent months, Strawberry Fields REIT has expanded its portfolio through the following acquisitions:

• Nine skilled nursing facilities in Missouri totaling 686 beds for $59 million. Eight of the facilities were added to an existing master lease with the Tide Group, increasing annual base rent by $5.5 million, while the ninth facility was added to Reliant Care Group’s lease, raising rent by an additional $0.6 million.
• An 80-bed skilled nursing facility near Oklahoma City, Oklahoma, for $4.25 million, which was leased to a current operator under a master lease with $425,000 of initial rents and 3% annual escalations.
• A 124-bed facility comprised of 108 skilled nursing beds and 16 assisted living beds near Poplar Bluff, Missouri, for $5.3 million, which was leased to a current operator under a master lease with $530,000of initial rents and 3% annual escalations.

Market Opportunity

Strawberry Fields REIT operates in the skilled nursing and post-acute healthcare real estate sector, which is supported by favorable demographic and regulatory trends. The U.S. population aged 65 and older is expected to exceed 72 million by 2030 and reach 88.5 million by 2050. According to the CDC, 83.5% of skilled nursing facility residents are 65 or older.

The sector benefits from high barriers to entry, including regulatory constraints, capital requirements, and operational complexity. At the same time, government programs such as Medicare and Medicaid provide a stable reimbursement base. The company noted that despite challenges, its operators have demonstrated consistent profitability in states that are traditionally considered difficult for SNF operators.

Spending on SNF care for the aging population is projected to grow from $181.6 billion in 2021 to $273 billion in 2030, reflecting a compound annual growth rate of 4.63%. Strawberry Fields REIT’s geographic clustering strategy and long-term lease structure position it to benefit from this increasing demand and constrained supply.

Leadership Team

Moishe Gubin, Chairman, CEO, and Founder, has served as CEO since the company’s inception and was involved in every acquisition. He previously served as CFO and manager of Infinity Healthcare Management and is a licensed CPA in New York.

Jeffrey Bajtner, Chief Investment Officer and Chief Operating Officer, joined the company in 2021. He oversees acquisitions, dispositions, and investor relations. Previously, he held leadership roles at BlitzLake Partners and NorthStar Realty Finance. He is a licensed CPA in Illinois.

Greg Flamion, Chief Financial Officer, joined in January 2024. He was formerly CFO at Zimmerman Advertising and has held senior finance roles at Diageo and Bristol Myers Squibb. He holds an MBA from the University of Florida and is a CPA licensed in Indiana.

Steven Greenfield, General Counsel, joined in April 2025. He previously served as Managing Attorney at HammondLaw and held executive and legal positions at Weil, Gotshal & Manges LLP and Mayer Brown LLP, focusing on tax and securities law.

Strawberry Fields REIT Inc. (NYSE American: STRW), closed Friday's trading session at $13.12, up 2.0218%, on 20,759 volume. The average volume for the last 3 months is 22,248 and the stock's 52-week low/high is $8.7/$14.

Recent News

• Strawberry Fields REIT Inc. (NYSE American: STRW) - MissionIRNewsBreaks - Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) to Report Year-End 2025 Financial Results Feb. 19
• NetworkNewsBreaks - Stewards Inc. (OTC: SWRD) Appoints John Bode to Board as Audit Committee Chair
• Strawberry Fields REIT Inc. (NYSE American: STRW) CEO Highlights Discipline, Scale, and Steady Returns at NobleCon21

Xeriant Inc. (OTCQB: XERI)

The QualityStocks Daily Newsletter would like to spotlight Xeriant Inc. (OTCQB: XERI).

In flood-risk discussion, some policymakers, researchers and industry observers have turned toward mitigation strategies that reduce the risk of damage in the first place.

Xeriant's NEXBOARD is a patent-pending composite panel engineered to outperform traditional building materials in multiple stress conditions, including floods.

NEXBOARD's water resistance isn't incidental; it reflects a deliberate emphasis on durability under challenging environmental conditions.

Lawmakers in Washington are discussing the future of flood insurance and whether the federal government or private insurers should shoulder the risk. As the discussion continues, attention is also turning to how communities can actually reduce flood damage rather than simply reallocate who pays for it. This discussion mirrors broader questions about resilience, infrastructure and risk mitigation in a world with increasingly frequent and severe flooding events. These questions are creating opportunities for companies focused on developing more durable, water-resistant building materials. Among those innovators, Xeriant (OTCQB: XERI) is advancing composite panel technology designed to withstand water exposure and other environmental stressors that can exacerbate flood losses.

Xeriant Inc. (OTCQB: XERI) is dedicated to the discovery, development and commercialization of emergent, transformative technologies, focusing on eco-friendly advanced materials with applications across multiple industries.

The company builds its technology portfolio through strategic partnerships, acquisitions, and internal development programs, emphasizing diversification and synergy, and is supported by its innovation platform called Factor X Research Group. Xeriant’s affiliated entities maintain operational focus and expertise while becoming part of a collaborative interdisciplinary innovation hub aimed at enhancing capabilities and accelerating technology development and deployment.

Xeriant’s advanced materials line is marketed under the DUREVER™ brand and includes NEXBOARD™, a patent-pending composite construction panel made from recycled plastic and fiber waste, designed to replace drywall, plywood, OSB, MDF, MgO board and other construction panels.

The company is headquartered in Boca Raton, Florida.

Portfolio

NEXBOARD™

Xeriant’s primary commercial focus is NEXBOARD™, an eco-friendly composite construction panel made from recycled plastic and fiber waste and enhanced with the company’s proprietary nanotechnology-based fire retardant, marketed under the DUREVER™ brand. Internal tests have demonstrated exceptional fire resistance, including a five-minute torch test reaching up to 2,500ºF and an 80-minute high-heat evaluation exceeding 2,000ºF.

The company has completed multiple limited production runs and internal tests to support certification, with accredited agencies documenting materials, processes, and quality controls. Upcoming certification testing includes NFPA 286 and ASTM E84, along with structural and durability testing.

Factor X Research Group

Factor X is Xeriant’s advanced innovation division, established to accelerate high-impact technologies from concept to commercial deployment. Modeled after Lockheed’s Skunk Works™, the group brings together experts across advanced materials, aerospace, artificial intelligence, critical infrastructure, and related disciplines to streamline development and strengthen cross-functional collaboration.

Its expanded mandate includes identifying acquisition opportunities; targeting disruptive technologies in areas such as AI, quantum computing, and data science; and supporting products like NEXBOARD™ as they move through the company’s commercialization pipeline.

Under the leadership of Brig. Gen. (Ret.) Blaine D. Holt, Factor X provides a coordinated environment designed to unify technical teams, reduce development barriers, and advance innovations with near-term market potential.

Market Opportunity

Xeriant operates at the intersection of several rapidly expanding sectors, including advanced aerospace systems, sustainable construction materials, and next-generation industrial technologies. Demand for eco-friendly building materials continues to accelerate, with the green construction market projected to reach $1.8 trillion by 2030, according to a World Economic Forum report, supported by rising global standards for safety, sustainability, and carbon reduction. NEXBOARD also participates in the broader fire-protection materials market, which is projected to grow from $37.69 billion in 2025 to $59.9 billion by 2034, according to Market Research Future, driven by stricter building codes and increasing awareness of fire-resistant alternatives.

Xeriant plans to capitalize on opportunities emerging from green construction, modular homebuilding, advanced composites engineering, nanotechnology, thermal-management innovations, and cross-disciplinary integration for new product development. Each prospective technology undergoes rigorous due diligence, including market forecasting, management evaluation, competitive assessment, and financial analysis, allowing Xeriant to pursue selective, strategically aligned acquisitions and partnerships.

Leadership Team

Keith F. Duffy, Chairman and Chief Executive Officer, has more than 30 years of experience across investment banking, finance, strategic planning, and operations, and has served as a principal in multiple start-ups spanning aviation, software, banking, and biotech. He arranged the merger that created Xeriant, established the company’s partnership with Florida Atlantic University, and previously held roles ranging from securities broker to controller of an aviation FBO. He is a licensed real estate and mortgage professional and holds a B.A. in Business Administration and Mathematics from Rollins College.

Scott M. Duffy, Executive Director of Corporate Operations, has built a career of over 30 years in management, operations, strategic planning, IT, marketing, and distribution, including oversight of a $545 million retail sales division at American Media. He has collaborated on business development efforts for several start-ups, including Xeriant, and has held senior roles supporting large-scale operational and administrative functions. He earned a B.A. in Business Administration and Mathematics from Rollins College.

Pablo Lavigna, Chief Information Officer, has more than 20 years of experience in information technology and software engineering, supporting Xeriant through technology sourcing, internal systems management, and the development of security and software solutions. His background includes directing IT operations for private firms and implementing network security and specialized software tools across multiple industries. He holds Microsoft and CompTIA certifications and graduated magna cum laude from Florida International University with a degree in Information Technology and Business.

Brian Carey, Chief Financial Officer, has spent over 30 years in accounting, tax, financial management, and business development, having founded and operated a long-standing accounting and advisory firm serving start-ups and established companies. His experience includes business planning, financial oversight, and operational support for partner organizations. He holds a Bachelor of Accounting degree from Penn State University.

Brig. Gen. (Ret.) Blaine D. Holt, President of Factor X Research Group, has a distinguished background in multinational operations, aerospace leadership, and technology-driven enterprise, including service as Deputy U.S. Military Representative to NATO and as a command pilot with more than 3,900 flight hours. His experience spans advanced manufacturing, AI-enabled logistics, large-scale aviation turnarounds, and advisory work supporting emerging technologies, strengthening Xeriant’s ability to evaluate and advance high-impact innovations.

Xeriant Inc. (OTCQB: XERI), closed Friday's trading session at $0.0098, up 0.7712082%, on 252,745 volume. The average volume for the last 3 months is 1,365,150 and the stock's 52-week low/high is $0.003735/$0.02.

Recent News

• Xeriant Inc. (OTCQB: XERI) - Xeriant Inc. (XERI) Water-Resistant Panels Offer Potential Impact on Flood-Risk Discussion
• Xeriant Inc. (XERI) Innovative Building Materials Answer Growing Calls for Lower Housing Costs
• Xeriant Inc. (XERI) Expands Leadership Role for Prominent Military Veteran to Drive Innovation

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Meta and Microsoft are set to open the latest round of Big Tech earnings, with investors watching closely to see whether massive spending on AI is translating into durable growth. The scrutiny comes as Alphabet has recently gained momentum, reshaping expectations in an increasingly competitive AI landscape. Together with Amazon, the companies are projected to boost spending on AI-related infrastructure and development by roughly 30% this year, pushing total outlays beyond $500 billion. The Google parent also opened a new line of business last fall, supplying its in-house AI chips to Anthropic. The multibillion-dollar deal marked a shift from its previous policy of keeping the technology for internal use. Meta is expected to report solid sales growth of over 20%, driven by AI-powered improvements in advertising tools, though heavy spending on elite engineering talent is likely to weigh on profits. Amazon's revenue is forecast to grow at a slower pace of 12.5% as its core North American retail operation shows signs of cooling. As most attention remains focused on those tech giants, other firms like D-Wave Quantum Inc. (NYSE: QBTS) are making progress in their bid to advance other verticals within the tech industry, and these advances could revolutionize many industries while setting the companies up for solid earnings growth in the years to come. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $21.22, off by 8.6133%, on 31,259,663 volume. The average volume for the last 3 months is 37,752,537 and the stock's 52-week low/high is $4.45/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Investors Watch Big Tech Earnings as Questions on AI Rally Linger
• China Appears to Be Quietly Winning the AI Dominance War
• How Bitcoin is Already Being Impacted by Quantum Computing

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is signaling a major leap forward in establishing a secure Western supply chain for heavy rare earth elements, with plans ramping up for commercial operations targeted in Louisiana in 2026. "The company recently released detailed information about significant progress on its proprietary rapid-separation technology and its transition from demonstration testing in Canada toward full deployment at a U.S. facility that could help reduce longstanding dependencies on foreign processors," reads a recent article. "The announcement underscores not only technological advancement but also strategic alignment with North American critical-mineral security goals."

To view the full article, visit https://ibn.fm/kGMLm

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Friday's trading session at $6.13, off by 15.3067%, on 668,967 volume. The average volume for the last 3 months is 723,890 and the stock's 52-week low/high is $0.4445/$10.69.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - RockBreaks - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Major Progress Toward Commercial Ramp-Up
• Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) Enters New Year with Key Processing Milestones in Sight
• RockBreaks - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Backs Section 232 Actions Targeting Critical Minerals Processing

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in the brains of mice. This has created hope that the compound could, in future, be made into a pill that can treat glioblastoma, one of the deadliest forms of brain cancer. Hui Li, PhD, who led the study team, explains that compound A, as the substance is known, attached to a target on glioblastoma that hadn't been known to serve as a therapeutic target. The researchers used mouse models in their study and they are now working to develop variants of compound A that are suitable for use in clinical trials. So far, 160 versions of this molecule have been created. The scientists then conducted a variety of tests on mice using compound A and found that it met the requirements of lowering the volume and size of GBM tumors. That happened even in tests in which the cancer had developed resistance to the drug temozolomide. Another exciting discovery was that the compound was even more effective at killing the stem cells of the cancer, which offered hope that the cancer could struggle to develop resistance to compound A. This preclinical study is significant in many ways, including the compound having the capability of being administered orally, showing efficacy against many GBM cell lines while also being able to cross the BBB (blood-brain barrier). The scientific community is eager to see how the drug will perform in the planned clinical trials once the researchers complete their experiments geared at having versions suitable for use by humans. Entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are also engaged in developing drugs for brain cancer are likely to be rooting for this team since they are all working to transform brain cancer care, in different ways. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $5.58, off by 3.6269%, on 33,991 volume. The average volume for the last 3 months is 63,789 and the stock's 52-week low/high is $4.93/$114.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - New Compound Could Become a Transformational Brain Cancer Pill
• TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287
• New Digital Twin Predicts Outcomes of Brain Cancer Treatments 

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

Beeline Holdings (NASDAQ: BLNE) , a fast-growing digital mortgage platform redefining the path to homeownership, announced it will host a stakeholder update call to review results for the fourth quarter of 2025 on Monday, March 30, 2026, at 5 p.m. ET. The call will be hosted by Nick Liuzza, Chief Executive Officer, and Chris Moe, Chief Financial Officer, who will discuss the company's performance and provide updates on ongoing initiatives.

To view the full press release, visit https://ibn.fm/QHyq3

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Friday's trading session at $3.03, off by 8.4592%, on 973,013 volume. The average volume for the last 3 months is 1,124,969 and the stock's 52-week low/high is $0.6202/$8.4.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - TechMediaBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Schedules Q4 2025 Stakeholder Update Call
• Beeline Holdings, Inc. (NASDAQ: BLNE) CEO Details 2025 Milestones and Strategic Priorities
• CryptoNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Publishes CEO Shareholder Letter Highlighting 2025 Milestones and 2026 Growth Outlook

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

The World Health Organization's recent recognition of rare diseases as a global health priority underscores their collective impact.

Soligenix remains focused on delivering meaningful progress in rare disease-based therapeutics and public health.

In its Specialized Biotherapeutics segment, Soligenix is advancing candidates designed for orphan diseases and other serious conditions where treatment options are limited.

As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and diagnostic delays can persist for years, prolonging suffering and reducing quality of life. Amid this growing demand, Soligenix (NASDAQ: SNGX) is advancing a diversified pipeline of specialized biotherapeutics and public health solutions targeting rare and orphan conditions as it heads into 2026.

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Friday's trading session at $1.25, off by 4.5802%, on 265,330 volume. The average volume for the last 3 months is 205,154 and the stock's 52-week low/high is $1.09/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
• InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)
• Meta Analysis Finds That Weight Reduction Reduces Severity of Psoriasis

ParaZero Technologies Ltd. (NASDAQ: PRZO)

The QualityStocks Daily Newsletter would like to spotlight ParaZero Technologies Ltd. (NASDAQ: PRZO).

ParaZero Technologies (NASDAQ: PRZO) , an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems ("UAS") industry, announced it has received a second substantial order from a major global defense corporation for its advanced interception net-pods. The follow-on order builds on prior success with the same strategic partner and reflects growing demand for ParaZero's counter-UAS technologies, with operational net-pods designed to address a broad range of aerial drone threats through precise, kinetic interception that minimizes collateral damage. The company's DefendAir system, incorporating patented net-launching technology, has demonstrated exceptional performance, including 100% interception success in prior field trials, positioning it as a critical layer in modern multi-layered counter-drone defense strategies.

To view the full press release, visit https://ibn.fm/OueJI

ParaZero Technologies Ltd. (NASDAQ: PRZO) is a defense aerospace company specializing in multi-layered Counter-Unmanned Aircraft System (“Counter-UAS”) technologies engineered to neutralize hostile drones in complex, contested, and urban environments. Founded by aviation and defense technology professionals, the company develops autonomous interception and precision-delivery systems that support military forces, homeland security agencies, and operators of strategic infrastructure. ParaZero’s mission is to provide reliable, practical, and scalable counter-drone capabilities for frontline and fixed-site defense scenarios where rapid, accurate, and low-collateral response is essential.

As drone threats evolve from low-cost commercial platforms to fast, low-signature systems operating in RF-denied conditions, ParaZero focuses on solutions that deliver actionable last-layer defense. Its technologies integrate with existing detection and command systems, allowing operators to respond effectively across military bases, sensitive facilities, border regions, and high-risk operational zones. The company’s defense portfolio continues to expand through field collaboration with Israeli defense authorities and international security organizations seeking capable interception systems.

Building on more than a decade of engineering and operational experience, ParaZero offers autonomous counter-drone and precision-delivery capabilities designed for modern defense requirements.

The company is headquartered in Kfar Saba, Israel.

DefendAir

DefendAir is ParaZero’s multi-layered Counter-UAS system designed to intercept hostile drones with high accuracy and minimal collateral damage. The platform employs patented net-interception technology and supports defense forces protecting bases, critical infrastructure, government facilities, and frontline units. Company-reported demonstrations conducted with Israeli defense and homeland security authorities have shown successful interception across a range of real-time scenarios involving fast, maneuverable, and RF-denied drones.

DefendAir is deployed through three complementary delivery mechanisms that enable flexible interception across dynamic battlefield and fixed-site environments:

• Interception Drone – The airborne configuration places a net-interception pod on an autonomous multirotor, enabling rapid engagement of hostile drones approaching from extended ranges or complex angles. This mobile layer offers adaptable response options where ground-based systems may have limited reach.
• Stationary Turret – The turret provides automated 360-degree perimeter coverage for fixed sites. Using optical detection and autonomous tracking, it identifies and intercepts approaching drones with a non-explosive, low-collateral method suitable for urban or sensitive environments.
• Hand-Held Net Launcher – The hand-held launcher offers infantry and security personnel a lightweight, tactical close-range interception tool. It enables unit-level drone neutralization in environments where jamming or spoofing is ineffective, providing a practical last-line defense option.

Together, these configurations provide flexible interception capabilities for a wide range of defense and security missions.

DropAir

DropAir is ParaZero’s high-accuracy aerial delivery solution engineered for autonomous or remotely controlled missions in complex and hostile environments. The system enables safe, precise delivery of sensitive payloads, including medical supplies, blood transfusions, tactical equipment, and humanitarian aid, without requiring the drone to land or expose ground personnel to risk. Its HALO-style late parachute deployment minimizes drift and lowers detectability, supporting both multirotor and fixed-wing UAVs.

DropAir has demonstrated operational effectiveness in collaboration with the Israeli Ministry of Defense and the Israel Defense Force Medical Corps, including a breakthrough field trial in which blood transfusions dropped from 200 meters were recovered fully intact and suitable for human use.

The system’s modular pod design secures a variety of payloads and is adaptable to a wide range of UAV platforms, with carrying capacities of 5, 10, or 20 kilograms depending on drone capability. Built for rapid deployment and all-weather performance, DropAir provides reliable resupply options for defense, disaster response, and remote operations where conventional logistics cannot safely reach.

Market Opportunity

ParaZero operates within rapidly expanding segments of the global unmanned systems and defense markets. According to Fortune Business Insights, the anti-drone (counter-UAS) market was valued at $2.4 billion in 2024 and is projected to grow from $3.1 billion in 2025 to $12.24 billion by 2032, reflecting a compound annual growth rate of 21.62%. This expansion is driven by the increasing use of drones in modern conflicts, the emergence of new threat types such as RF-denied and fiber-optic-guided drones, and the need to protect critical infrastructure, military bases, and sensitive facilities.

The precision airdrop category is also gaining traction as defense forces and emergency agencies seek secure, rapid, and unmanned delivery solutions for time-critical missions. ParaZero’s DropAir program has advanced into Phase II with the Israeli Defense Force Medical Corps, highlighting governmental adoption of autonomous delivery technologies for military and humanitarian use.

Leadership Team

Ariel Alon, Chief Executive Officer, is an experienced executive with a proven track record of leading high-performing business teams across unmanned aircraft systems, finance, high-tech, defense, and government sectors in Israel, the U.S., EMEA, and APAC. Prior to joining ParaZero, he served as Chief Sales Officer of Aerodrome Group and CEO of its subsidiary, Aerodrome LTD. His earlier roles include vice president of sales and general manager for Israel at Voyager Labs, Israeli country manager for Atos, and business development positions at companies including Elbit Systems and Rafael Advanced Defense Systems. Mr. Alon holds a B.A. in business administration and an M.B.A. in finance and marketing from the Ruppin Academic Center in Israel.

Regev Livne, Chief Financial Officer, previously served as CFO of Votiro, where he raised capital and supported the company’s expansion into North America and Asia. His earlier experience includes serving as CFO of SCR Engineers Ltd., along with finance roles at 3M Attenti and Dmatek Ltd. Mr. Livne began his career as a senior accountant at PwC Israel, auditing both public and private companies. He is a Certified Public Accountant in Israel and holds a master’s degree in finance and management and a B.A. in business administration and accounting from the Israeli College of Management.

Alon Yasovsky, Vice President of R&D, is an engineering leader with more than 20 years of experience across electro-optics, machine vision, embedded systems, and advanced technology development. He previously worked in Samsung Electronics Israel’s Open Innovation group and evaluated R&D investments for the Israeli Innovation Authority. Earlier in his career, he held engineering and leadership roles at SensoGenic, Kornit Digital, Intel, Apple, PrimeSense, and Elbit Systems. Mr. Yasovsky holds a B.Sc. in electrical and electronic engineering from Tel Aviv University and completed the U.S.–Israel Innovation Bridge Leadership Executives Program at the University of California, Irvine.

Paid Promotional Disclosure

This press release constitutes a paid promotional communication. The Company has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this press release, and has paid a fee for such services. The Company exercises editorial control over the content of this press release but does not control how, when, or to whom the information is distributed by such third party.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. Investing in securities involves significant risks, and readers are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.

ParaZero Technologies Ltd. (NASDAQ: PRZO), closed Friday's trading session at $1.13, off by 6.6116%, on 1,556,605 volume. The average volume for the last 3 months is 2,329,094 and the stock's 52-week low/high is $0.5255/$2.145.

Recent News

• ParaZero Technologies Ltd. (NASDAQ: PRZO) - DefenseNewsBreaks - ParaZero Technologies Ltd. (NASDAQ: PRZO) Secures Second Net-Pod Order From Major Global Defense Contractor
• DefenseNewsBreaks - ParaZero Technologies Ltd. (NASDAQ: PRZO) Expands European Footprint With New NATO-Aligned Reseller Agreement
• TinyGemsBreaks - ParaZero Technologies Ltd. (NASDAQ: PRZO) Highlights 2025 Advancements Driving DefendAir Counter-UAS Momentum

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) announced it has identified a robust near-term drilling target for a second Natural Hydrogen play concept in Saskatchewan, advancing toward licensing to commence the Bracken well along the Saskatchewan-Montana border in February. Building on its confirmed Natural Hydrogen discovery at Lawson within the 475-km Genesis Trend, the Company is progressing analytical testing, resource modeling, and estimation while simultaneously expanding exploration to demonstrate basin-scale continuity and scalability. The Bracken target was generated through an integrated geophysical and geological workflow using newly acquired proprietary 2D seismic and legacy data, and will test a stratigraphic play concept distinct from the structural model at Lawson, with potential associated helium, supported by the Company's AI-assisted MAXX LEMI platform.

To view the full press release, visit https://ibn.fm/dNp0U

Copper dominated commodity headlines as disruptions, tariffs and volatile pricing reshaped the market, prompting a look back at the forces that defined 2025. The year proved pivotal, with demand strengthening on the back of accelerating electrification and growing optimism around artificial intelligence and the expanding data infrastructure it requires. This combination of tightening supply, policy uncertainty and a robust demand outlook pushed prices to historic levels late in the year, a rally that extended into early 2026, culminating in LME copper cash prices surpassing $13,000 per ton. In addition to the above, America's trade policy also had a huge impact on the copper market last year, starting with a Section 232 investigation that led President Donald Trump to announce a 50% tariff on copper imports mid-year. The threat of tariffs also prompted a surge in America's import activity, including a significant increase in shipments from Chile despite an overall decline in the country's refined copper exports. Overall, last year marked a turning point for the copper market, with strengthened demand pushing prices to historic highs. With these structural pressures still unresolved, the red metal enters 2026 facing continued volatility and a market increasingly shaped by geopolitics as much as fundamentals. Geopolitics and shifting trade policies aren't only affecting the copper market. Even companies like Max Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) are also having to contend with the same challenges in their bid to extract natural hydrogen to power the energy transition. 

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Friday's trading session at $0.7724, off by 2.2897%, on 115,774 volume. The average volume for the last 3 months is 1,011,660 and the stock's 52-week low/high is $0.105/$0.8791.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - MiningNewsBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Identifies Near-Term Bracken Well Target for Second Natural Hydrogen Play in Saskatchewan
• Analyzing the Key Drivers of the Copper Market in 2025
• MiningNewsBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Confirms First-Ever Subsurface Natural Hydrogen System in Canada

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

ESGold Corp., an exploration-stage company committed to the acquisition, exploration, and development of mineral properties worldwide, and rapidly approaching production, is becoming a serious alternative to gold or silver for those hedging themselves against inflation

With gold prices recently surpassing $5,300 an ounce, and silver $110, many people have been priced out of purchasing the commodity

Investing in companies already in this space, and beginning to make significant moves, offers an affordable option to direct gold ownership

ESGold (CSE: ESAU) (OTCQB: ESAUF) , an exploration-stage company committed to acquiring, exploring, and developing high-quality mineral properties, represents a more affordable way to benefit from soaring gold and silver prices than direct precious metal ownership.

ESGold (CSE: ESAU) (OTCQB: ESAUF) is an exploration-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide. According to a recent article, the company "is going into 2026 strong on the heels of a closed flow-through share private placement and incredible progress on its Montauban project exploration. The partial completion and interpretation of a comprehensive three-dimensional geological model on the property demonstrated that Montauban is not just a reclamation story, but the nucleus of a potentially much larger gold, silver, and base-metal district. "The Montauban model is the most significant technical milestone in the project's modern history," noted ESGold's CEO and Director, Gordon Robb. "What was once seen as a series of small, isolated deposits now seems to emerge as a continuous multilayered mineral system with dimensions not previously recognized at Montauban ."

To view the full article, visit https://ibn.fm/FgdoQ

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

ESGold Corp. (OTCQB: ESAUF), closed Friday's trading session at $0.56, off by 8.9875%, on 208,309 volume. The average volume for the last 3 months is 276,150 and the stock's 52-week low/high is $0.139/$1.1.

Recent News

• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) A More Affordable Entry to Gold or Silver Investment
• RockBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Eyes Expanded Gold, Silver and Base-Metal Potential at Montauban
• MiningNewsBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Gains Momentum as Montauban Shows District-Scale Potential

Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF)

The QualityStocks Daily Newsletter would like to spotlight Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF).

Disseminated on behalf of Fairchild Gold Corp. (TSX.V: FAIR) (OTCQB: FCHDF) and may include paid advertising.

Copper prices have surged above $6 per pound, highlighting long-term supply constraints connected to infrastructure and electrification buildouts

Fairchild Gold is advancing gold and copper exploration assets in North America, a region quickly gaining strategic importance

These updates highlight Fairchild's focus on metals critical to both macroeconomic resilience and industrial growth

Fairchild (TSX.V: FAIR) (OTC: FCHDF) is consolidating its investments in gold and copper, two critical metals in today's global economy. With markets confronting a structural shift in the way supply chains, energy, and infrastructure are developed, the company is strategically positioned to leverage the latest developments. The recent rise in the price of copper to over $6 per pound, exceeding its July 2025 high, underscores increased global supply pressures at a time when decarbonization and electrification are picking up steam globally ( ibn.fm/l82yn ).

Fairchild Gold (TSX.V: FAIR) (OTCQB: FCHDF) was featured in a recent article that discussed its exploration efforts at the Nevada Titan Project, strategically positioning the company to capitalize on long-term trends in both the gold and copper markets. The publication reads, "The Nevada Titan project, located 26 miles southwest of Las Vegas, features geological characteristics consistent with a potential porphyry-style system. Over the past year, Fairchild has identified a 1.5-kilometer discontinuous copper trend, accompanied by additional high-grade occurrences at strategic mine sites, including Copper Chief, Azurite, Fitzhugh, and Copperside. Historical data and surface sampling indicate a broad, oxidized, and mineralized footprint, and magnetic surveys have identified eight priority targets for follow-up exploration."

To view the full article, visit https://ibn.fm/m0VSq

Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) is a mineral exploration company focused on acquiring, exploring, and developing high-quality mineral properties in mining-friendly jurisdictions across North America. The company targets projects with historical production, strong multi-metal potential, and clear pathways to discovery through modern geoscience, AI integration, and responsible development practices.

Fairchild’s portfolio is anchored by the Nevada Titan Project, a district-scale, copper-gold system located just outside Las Vegas in the prolific Walker Lane Belt. The company has also entered into an MOU to acquire the advanced-stage Golden Arrow Project in Nevada, subject to completion of a definitive agreement, and it holds 100% ownership of the Fairchild Lake Property in Ontario.

Fairchild’s mission is to build long-term value by identifying overlooked mineralized systems and unlocking their potential using modern exploration methods.

The company is headquartered in Vancouver, British Columbia.

Projects

Nevada Titan Project (Goodsprings District, Nevada)

Nevada Titan is Fairchild’s flagship asset and a district-scale, multi-metal opportunity located just 55 kilometers southwest of Las Vegas. Spanning over 6,150 acres (300+ claims), the project sits within the historically productive Goodsprings Mining District—part of the prolific Walker Lane Belt and Battle Mountain Trend extension. The area hosts numerous historic mines, including Copperside, Copper Chief, Azurite, and Fitzhugh Lee, yet remains largely untested by modern drilling.

Surface sampling and geological mapping have confirmed high-grade copper mineralization up to 34.0% Cu, with associated values of gold, silver, molybdenum, and platinum group elements. A 1.5-kilometer copper-gold corridor has been identified, showing pods and lenses of mineralization consistent with a porphyry-skarn-CRD system. Notably, the discovery of a hydrothermal breccia pipe with garnet-bearing skarn textures and elevated molybdenum signals a porphyry-affiliated source at depth.

Ongoing exploration includes drone magnetics, AI-integrated targeting, and induced polarization geophysics. With infrastructure already in place and proximity to Las Vegas contractors, Fairchild is preparing for a 2026 drill campaign focused on unlocking the project’s large-scale copper-gold system.

Golden Arrow Project (Walker Lane Shear Zone, Nevada)

In September 2025, Fairchild signed a Memorandum of Understanding to acquire 100% of the Golden Arrow Project, an advanced-stage gold-silver asset in Nevada’s Walker Lane Trend. The project hosts a historic mineral resource estimate of approximately 347,000 ounces of gold and 5.3 million ounces of silver, including 296,500 ounces of gold and 4.0 million ounces of silver in the measured and indicated categories. According to third-party analysis by mining analyst Ryan D. Long, the total acquisition consideration of $5.0 million equates to approximately $12 per ounce of gold in the ground.

The project’s two main deposits, Gold Coin and Hidden Hill, were historically mined at surface and remain open at depth, supported by over 61,000 meters of past drilling. Modern geophysical work has outlined 34 additional exploration targets, including six classified as high-priority. Hosted in a volcanic complex with both high-grade vein and disseminated mineralization, the system offers strong potential for expansion.

Golden Arrow is situated just 96 kilometers from Kinross’s 28-million-ounce Round Mountain Mine and expands Fairchild’s Nevada footprint by 170% when combined with the Titan Project. The project’s extensive exploration database and near-surface deposits make the acquisition a compelling strategic entry point into a proven district with significant near-term development potential.

Fairchild Lake Property (Savant Lake Greenstone Belt, Ontario)

Fairchild Gold holds 100% ownership of the Fairchild Lake Property, a 2,224-hectare claim package in Ontario’s underexplored Savant Lake greenstone belt. Historical and recent work, including airborne geophysics and soil sampling, has identified anomalous gold values near the Kashaweogama Lake Fault, a major crustal break. The company draws geological comparisons to Red Lake’s LP Fault and views the structural setting as a promising focus for future exploration.

Market Opportunity

Fairchild operates in Tier-1 mining jurisdictions where political stability, established infrastructure, and clear permitting pathways reduce development risk and enhance long-term value. Nevada, in particular, is a top-ranked global destination for mineral exploration and home to some of the world’s most productive gold and copper belts. Fairchild’s flagship project, Nevada Titan, is located in the Walker Lane Belt, a prolific trend responsible for more than 89 million ounces of gold and nearly 1 billion ounces of silver to date.

The company is strongly positioned to benefit from the ongoing historic bull market in gold. In early October 2025, Goldman Sachs raised its December 2026 gold price forecast to $4,900 per ounce, citing strong ETF inflows and sustained central bank demand. A Jefferies analyst has projected gold could reach $6,600 per ounce in the near term, while other major institutions including UBS and Bank of America have also raised their targets amid elevated geopolitical risk, structural reserve diversification, and anticipated U.S. rate cuts. With limited new supply and rising demand from both institutional and retail investors, gold remains a cornerstone of portfolio hedging and upside exposure.

Copper also remains a core strategic focus, with demand expected to double by 2035, driven by electrification, grid modernization, and clean energy buildout, according to S&P Global. The Nevada Titan Project hosts porphyry-style copper-gold mineralization, along with skarn and carbonate replacement features—deposit types that are key global sources of both industrial and precious metals.

Leadership Team

Nikolas Perrault, CFA, Executive Chairman, brings over 35 years of experience in capital markets, securities trading, and strategic advisory roles. He began his career with Canada’s top financial institutions and has since focused on guiding small to mid-cap companies through public listings, M&A, and capital raising. He holds a Chartered Financial Analyst designation and a Bachelor of Commerce.

Luís Martins, President and CEO, brings over 40 years of experience in the exploration and mining sector. He previously served as Director of the Mineral Resources Department at Portugal’s Geological Survey and as Director of Mines and Quarries at the Directorate-General of Energy and Geology. He has coordinated international working groups focused on raw materials and mineral policy and has authored more than 100 scientific publications.

Dr. Sergei Diakov, Chair of the Technical Committee and Senior Advisor, is a globally recognized geologist and former discovery lead at both BHP and AngloGold Ashanti. His track record includes major copper-gold discoveries such as Oyu Tolgoi in Mongolia and Nuevo Chaquiro in Colombia. Dr. Diakov brings decades of senior experience managing exploration teams, overseeing risk across geologic and ESG domains, and executing discovery-driven development strategies.

Adam Cavise, Independent Director, brings over 25 years of capital markets experience and has been directly involved in structuring and closing more than $100 billion in public and private equity offerings, SPACs, and recapitalization transactions. Currently a partner at Revere Securities in New York, he has held senior equity roles at Kingswood, Spartan Capital, and Macquarie, and is well regarded for his deep Wall Street network and leadership in equity capital markets.

Fairchild Gold benefits from a deeply experienced leadership and advisory team with expertise across exploration, capital markets, and corporate development. To view the full team, click here.

Fairchild Gold Corp. (OTC: FCHDF), closed Friday's trading session at $0.0581, off by 12.6972%, on 107,950 volume. The average volume for the last 3 months is 430,690 and the stock's 52-week low/high is $0.0306/$1.

Recent News

• Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) - Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) Positions for Structural Copper Strength as Global Supply Tightens
• MiningNewsBreaks - Fairchild Gold Corp. (TSX.V: FAIR) (OTCQB: FCHDF) Identifies Multiple Priority Targets at Nevada Titan Project
• InvestorNewsBreaks - Fairchild Gold Corp.'s (TSX.V: FAIR) (OTCQB: FCHDF) Nevada Titan Project Shows High-Grade Copper Potential in Nevada